Free Trial
NASDAQ:BCTX

BriaCell Therapeutics 3/17/2025 Earnings Report

BriaCell Therapeutics logo
$3.12 -0.41 (-11.61%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$3.15 +0.03 (+0.96%)
As of 06/13/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BriaCell Therapeutics EPS Results

Actual EPS
-$2.33
Consensus EPS
-$1.94
Beat/Miss
Missed by -$0.39
One Year Ago EPS
N/A

BriaCell Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

BriaCell Therapeutics Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

BriaCell Therapeutics Earnings Headlines

BriaCell Therapeutics (BCTX) Projected to Post Earnings on Friday
Trump’s Manhattan Project
The President’s tour of the Middle East… the deal for Ukraine’s mineral rights… Elon’s strange time in Washington… even Trump’s obsession with seizing Greenland. There’s a singular force that connects the dots… And it could threaten to transform American life – and your wealth – forever.
See More BriaCell Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BriaCell Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BriaCell Therapeutics and other key companies, straight to your email.

About BriaCell Therapeutics

BriaCell Therapeutics (NASDAQ:BCTX), a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

View BriaCell Therapeutics Profile

More Earnings Resources from MarketBeat